Avid Bioservices, Inc. (CDMO)
USD 12.49
(0.0%)
USD 12.49
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 336.55 Million USD | -25.38% |
| 2023 | 451.05 Million USD | 4.93% |
| 2022 | 429.84 Million USD | 61.89% |
| 2021 | 265.51 Million USD | 146.71% |
| 2020 | 107.62 Million USD | 37.28% |
| 2019 | 78.39 Million USD | -18.13% |
| 2018 | 95.76 Million USD | -18.92% |
| 2017 | 118.11 Million USD | 8.32% |
| 2016 | 109.04 Million USD | 11.88% |
| 2015 | 97.46 Million USD | 7.64% |
| 2014 | 90.54 Million USD | 100.95% |
| 2013 | 45.05 Million USD | 59.43% |
| 2012 | 28.26 Million USD | -18.71% |
| 2011 | 34.76 Million USD | 18.51% |
| 2010 | 29.33 Million USD | 26.84% |
| 2009 | 23.12 Million USD | 0.3% |
| 2008 | 23.05 Million USD | 0.26% |
| 2007 | 22.99 Million USD | 1.42% |
| 2006 | 22.67 Million USD | 59.19% |
| 2005 | 14.24 Million USD | -25.56% |
| 2004 | 19.13 Million USD | 254.45% |
| 2003 | 5.39 Million USD | -31.36% |
| 2002 | 7.86 Million USD | -0.43% |
| 2001 | 7.9 Million USD | 32.71% |
| 2000 | 5.95 Million USD | -19.55% |
| 1999 | 7.4 Million USD | -38.33% |
| 1998 | 12 Million USD | -35.83% |
| 1997 | 18.7 Million USD | 73.15% |
| 1996 | 10.8 Million USD | 1100.0% |
| 1995 | 900 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 454.64 Million USD | 2.78% |
| 2024 Q1 | 442.33 Million USD | -1.93% |
| 2024 FY | 336.55 Million USD | -25.38% |
| 2024 Q4 | 336.55 Million USD | -26.07% |
| 2024 Q3 | 455.22 Million USD | 0.13% |
| 2023 FY | 451.05 Million USD | 4.93% |
| 2023 Q1 | 451.21 Million USD | 4.97% |
| 2023 Q2 | 441.85 Million USD | -2.08% |
| 2023 Q3 | 450.43 Million USD | 1.94% |
| 2023 Q4 | 451.05 Million USD | 0.14% |
| 2022 FY | 429.84 Million USD | 61.89% |
| 2022 Q1 | 270.53 Million USD | 1.89% |
| 2022 Q2 | 301.62 Million USD | 11.49% |
| 2022 Q3 | 314.09 Million USD | 4.13% |
| 2022 Q4 | 429.84 Million USD | 36.85% |
| 2021 FY | 265.51 Million USD | 146.71% |
| 2021 Q4 | 265.51 Million USD | 57.87% |
| 2021 Q3 | 168.17 Million USD | 48.05% |
| 2021 Q2 | 113.59 Million USD | 7.61% |
| 2021 Q1 | 105.56 Million USD | -1.91% |
| 2020 Q4 | 107.62 Million USD | 2.28% |
| 2020 FY | 107.62 Million USD | 37.28% |
| 2020 Q1 | 102.07 Million USD | 30.2% |
| 2020 Q2 | 105.25 Million USD | 3.12% |
| 2020 Q3 | 105.21 Million USD | -0.03% |
| 2019 Q4 | 78.39 Million USD | 3.0% |
| 2019 FY | 78.39 Million USD | -18.13% |
| 2019 Q1 | 84.7 Million USD | -11.54% |
| 2019 Q2 | 80.22 Million USD | -5.29% |
| 2019 Q3 | 76.11 Million USD | -5.13% |
| 2018 Q3 | 69.85 Million USD | -11.15% |
| 2018 Q4 | 95.76 Million USD | 37.08% |
| 2018 FY | 95.76 Million USD | -18.92% |
| 2018 Q1 | 100.27 Million USD | -15.1% |
| 2018 Q2 | 78.62 Million USD | -21.59% |
| 2017 Q3 | 111.31 Million USD | 1.26% |
| 2017 FY | 118.11 Million USD | 8.32% |
| 2017 Q1 | 105.6 Million USD | -3.15% |
| 2017 Q2 | 109.93 Million USD | 4.1% |
| 2017 Q4 | 118.11 Million USD | 6.1% |
| 2016 Q3 | 119.05 Million USD | 5.68% |
| 2016 Q4 | 109.04 Million USD | -8.41% |
| 2016 Q2 | 112.65 Million USD | 22.41% |
| 2016 Q1 | 92.03 Million USD | -5.57% |
| 2016 FY | 109.04 Million USD | 11.88% |
| 2015 FY | 97.46 Million USD | 7.64% |
| 2015 Q4 | 97.46 Million USD | 23.18% |
| 2015 Q1 | 87.6 Million USD | -3.24% |
| 2015 Q2 | 81.43 Million USD | -7.04% |
| 2015 Q3 | 79.12 Million USD | -2.84% |
| 2014 Q2 | 55.1 Million USD | 3.35% |
| 2014 Q4 | 90.54 Million USD | 18.38% |
| 2014 FY | 90.54 Million USD | 100.95% |
| 2014 Q1 | 53.32 Million USD | 18.34% |
| 2014 Q3 | 76.48 Million USD | 38.79% |
| 2013 FY | 45.05 Million USD | 59.43% |
| 2013 Q4 | 45.05 Million USD | 21.26% |
| 2013 Q3 | 37.15 Million USD | 1.72% |
| 2013 Q2 | 36.52 Million USD | 15.94% |
| 2013 Q1 | 31.5 Million USD | 11.48% |
| 2012 Q3 | 29.44 Million USD | 7.93% |
| 2012 Q1 | 27.01 Million USD | -22.29% |
| 2012 FY | 28.26 Million USD | -18.71% |
| 2012 Q2 | 27.27 Million USD | 0.97% |
| 2012 Q4 | 28.26 Million USD | -4.0% |
| 2011 Q1 | 29.3 Million USD | -0.12% |
| 2011 Q4 | 34.76 Million USD | -1.82% |
| 2011 FY | 34.76 Million USD | 18.51% |
| 2011 Q2 | 28.76 Million USD | -1.82% |
| 2011 Q3 | 35.41 Million USD | 23.08% |
| 2010 Q1 | 26.21 Million USD | 13.34% |
| 2010 FY | 29.33 Million USD | 26.84% |
| 2010 Q4 | 29.33 Million USD | 6.59% |
| 2010 Q3 | 27.52 Million USD | -0.03% |
| 2010 Q2 | 27.52 Million USD | 5.02% |
| 2009 Q4 | 23.12 Million USD | 1.32% |
| 2009 FY | 23.12 Million USD | 0.3% |
| 2009 Q3 | 22.82 Million USD | 4.96% |
| 2009 Q2 | 21.74 Million USD | -4.65% |
| 2009 Q1 | 22.8 Million USD | -1.08% |
| 2008 Q1 | 38.66 Million USD | 68.14% |
| 2008 FY | 23.05 Million USD | 0.26% |
| 2008 Q2 | 34.44 Million USD | -10.92% |
| 2008 Q3 | 28.24 Million USD | -18.01% |
| 2008 Q4 | 23.05 Million USD | -18.36% |
| 2007 FY | 22.99 Million USD | 1.42% |
| 2007 Q1 | 33.35 Million USD | 47.09% |
| 2007 Q3 | 28.37 Million USD | -4.81% |
| 2007 Q2 | 29.8 Million USD | -10.64% |
| 2007 Q4 | 22.99 Million USD | -18.94% |
| 2006 Q1 | 20.88 Million USD | 46.62% |
| 2006 FY | 22.67 Million USD | 59.19% |
| 2006 Q2 | 16.96 Million USD | -18.77% |
| 2006 Q4 | 22.67 Million USD | 9.15% |
| 2006 Q3 | 20.77 Million USD | 22.46% |
| 2005 Q3 | 15.32 Million USD | 5.23% |
| 2005 Q4 | 14.24 Million USD | -7.06% |
| 2005 Q2 | 14.56 Million USD | -13.81% |
| 2005 FY | 14.24 Million USD | -25.56% |
| 2005 Q1 | 16.89 Million USD | -11.7% |
| 2004 Q2 | 13.66 Million USD | 31.53% |
| 2004 Q4 | 19.13 Million USD | -5.61% |
| 2004 Q3 | 20.27 Million USD | 48.4% |
| 2004 Q1 | 10.38 Million USD | 92.39% |
| 2004 FY | 19.13 Million USD | 254.45% |
| 2003 Q2 | 9.92 Million USD | 107.97% |
| 2003 Q3 | 8.08 Million USD | -18.49% |
| 2003 Q4 | 5.39 Million USD | -33.23% |
| 2003 FY | 5.39 Million USD | -31.36% |
| 2003 Q1 | 4.77 Million USD | -39.36% |
| 2002 Q2 | 7.9 Million USD | -5.16% |
| 2002 Q1 | 8.33 Million USD | 5.48% |
| 2002 FY | 7.86 Million USD | -0.43% |
| 2002 Q4 | 7.86 Million USD | -37.96% |
| 2002 Q3 | 12.67 Million USD | 60.42% |
| 2001 Q4 | 7.9 Million USD | -24.16% |
| 2001 FY | 7.9 Million USD | 32.71% |
| 2001 Q3 | 10.41 Million USD | -16.51% |
| 2001 Q1 | 14.43 Million USD | 142.45% |
| 2001 Q2 | 12.47 Million USD | -13.56% |
| 2000 Q1 | 6.5 Million USD | -12.16% |
| 2000 Q2 | 3.1 Million USD | -52.31% |
| 2000 Q3 | 5 Million USD | 61.29% |
| 2000 Q4 | 5.95 Million USD | 19.06% |
| 2000 FY | 5.95 Million USD | -19.55% |
| 1999 FY | 7.4 Million USD | -38.33% |
| 1999 Q1 | 15.1 Million USD | 25.83% |
| 1999 Q2 | 11.7 Million USD | -22.52% |
| 1999 Q3 | 5.3 Million USD | -54.7% |
| 1999 Q4 | 7.4 Million USD | 39.62% |
| 1998 FY | 12 Million USD | -35.83% |
| 1998 Q3 | 12.9 Million USD | -14.0% |
| 1998 Q4 | 12 Million USD | -6.98% |
| 1998 Q2 | 15 Million USD | -12.79% |
| 1998 Q1 | 17.2 Million USD | -8.02% |
| 1997 Q4 | 18.7 Million USD | 117.44% |
| 1997 Q3 | 8.6 Million USD | -9.47% |
| 1997 FY | 18.7 Million USD | 73.15% |
| 1997 Q2 | 9.5 Million USD | -3.06% |
| 1997 Q1 | 9.8 Million USD | -9.26% |
| 1996 Q2 | 1.2 Million USD | 0.0% |
| 1996 Q3 | 7.2 Million USD | 500.0% |
| 1996 FY | 10.8 Million USD | 1100.0% |
| 1996 Q4 | 10.8 Million USD | 50.0% |
| 1995 Q4 | 900 Thousand USD | 0.0% |
| 1995 FY | 900 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 77.383% |
| Alkermes plc | 2.13 Billion USD | 84.245% |
| Agenus Inc. | 313.91 Million USD | -7.213% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 91.212% |
| Aptorum Group Limited | 20.64 Million USD | -1530.598% |
| Ardelyx, Inc. | 297.57 Million USD | -13.098% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 56.037% |
| Bicycle Therapeutics plc | 595.34 Million USD | 43.468% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -356.646% |
| ChromaDex Corporation | 54.96 Million USD | -512.323% |
| Chimerix, Inc. | 212.77 Million USD | -58.176% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1090.409% |
| Caribou Biosciences, Inc. | 440.96 Million USD | 23.678% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 84.905% |
| Precision BioSciences, Inc. | 159.78 Million USD | -110.636% |
| Dyadic International, Inc. | 8.21 Million USD | -3994.748% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -960.356% |
| Fortress Biotech, Inc. | 167.52 Million USD | -100.898% |
| Lantern Pharma Inc. | 43.64 Million USD | -671.078% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -108.605% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -2220.019% |
| Incyte Corporation | 6.78 Billion USD | 95.038% |
| IO Biotech, Inc. | 150.71 Million USD | -123.302% |
| Jaguar Health, Inc. | 50.76 Million USD | -562.997% |
| Novavax, Inc. | 1.85 Billion USD | 81.86% |
| Janux Therapeutics, Inc. | 380.4 Million USD | 11.527% |
| Opthea Limited | 188.79 Million USD | -78.269% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 59.6% |
| ContextLogic Inc. | 423 Million USD | 20.436% |
| MiMedx Group, Inc. | 239.04 Million USD | -40.791% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -93.729% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -6410.183% |
| NextCure, Inc. | 129.41 Million USD | -160.054% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -523.854% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -816.325% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -941.94% |
| Vaxcyte, Inc. | 1.4 Billion USD | 76.095% |
| PDS Biotechnology Corporation | 59.39 Million USD | -466.689% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 47.458% |
| Pharming Group N.V. | 462.85 Million USD | 27.287% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -770.106% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 46.455% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1678.497% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -1678.497% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -103.579% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -643.165% |
| Acelyrin, Inc. | 742.69 Million USD | 54.684% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -5009.783% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -5156.239% |
| Summit Therapeutics Inc. | 202.94 Million USD | -65.833% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -352.52% |
| Senti Biosciences, Inc. | 119.48 Million USD | -181.675% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -47.392% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -100.124% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -3973.061% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -6950.133% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 28.269% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -172.179% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -22.407% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 28.822% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -3230.599% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -56.899% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -29627.008% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | 18.675% |
| Immix Biopharma, Inc. | 19.92 Million USD | -1589.106% |
| Keros Therapeutics, Inc. | 370.02 Million USD | 9.045% |
| MEI Pharma, Inc. | 41.37 Million USD | -713.431% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -938.564% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | 1.244% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -187.103% |
| Fortress Biotech, Inc. | 167.52 Million USD | -100.898% |
| Precigen, Inc. | 151.04 Million USD | -122.822% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -889.35% |
| AlloVir, Inc. | 190.79 Million USD | -76.396% |
| C4 Therapeutics, Inc. | 376.45 Million USD | 10.597% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 33.515% |
| ImmuCell Corporation | 43.8 Million USD | -668.253% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 48.167% |
| Onconetix, Inc. | 88.82 Million USD | -278.914% |
| PureTech Health plc | 693.97 Million USD | 51.503% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -244.533% |
| Elevation Oncology, Inc. | 89.09 Million USD | -277.768% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -5326.588% |
| Seer, Inc. | 436.26 Million USD | 22.856% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -312.462% |
| Innoviva, Inc. | 1.24 Billion USD | 72.935% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -154.153% |
| ESSA Pharma Inc. | 149.12 Million USD | -125.692% |
| GlycoMimetics, Inc. | 45.31 Million USD | -642.681% |
| GT Biopharma, Inc. | 14.1 Million USD | -2285.406% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -9.31% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -39.244% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 28.681% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -563.86% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -253.482% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -53187.428% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 40.573% |
| Aptose Biosciences Inc. | 12.92 Million USD | -2504.418% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1421.899% |
| Soligenix, Inc. | 9.79 Million USD | -3335.192% |
| Century Therapeutics, Inc. | 360.69 Million USD | 6.691% |
| Kura Oncology, Inc. | 448.93 Million USD | 25.032% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -23.666% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -1845.979% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -203.447% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -64.053% |
| Autolus Therapeutics plc | 375.38 Million USD | 10.343% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -33.748% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | 5.244% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -585.006% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 49.094% |
| GRI Bio, Inc. | 2.95 Million USD | -11285.555% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -3073.501% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -97.377% |
| IGM Biosciences, Inc. | 423.41 Million USD | 20.513% |
| INmune Bio, Inc. | 57 Million USD | -490.441% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -51.257% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -300.944% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1188.658% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -4789.546% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -347.395% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -128.549% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -103.353% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 46.545% |
| Verastem, Inc. | 149.71 Million USD | -124.794% |
| Abeona Therapeutics Inc. | 64 Million USD | -425.854% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 34.286% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -117.897% |
| Histogen Inc. | 19.07 Million USD | -1664.573% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1385.891% |
| Surrozen, Inc. | 46.08 Million USD | -630.375% |
| Organovo Holdings, Inc. | 6.34 Million USD | -5200.945% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -7711.248% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -133.677% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -2751.695% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -347.145% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -3850.547% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | 7.277% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -1760.007% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | 21.622% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -2568.605% |
| Apollomics, Inc. | 55.38 Million USD | -507.646% |
| Amarin Corporation plc | 831.68 Million USD | 59.533% |
| Mesoblast Limited | 669.15 Million USD | 49.704% |
| Turnstone Biologics Corp. | 112.81 Million USD | -198.326% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 41.546% |
| Synaptogenix, Inc. | 31.11 Million USD | -981.701% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -2662.287% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 38.591% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -5631.302% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -4482.025% |
| Exelixis, Inc. | 2.94 Billion USD | 88.562% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1366.927% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | 7.676% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 57.329% |
| NLS Pharmaceutics AG | 1.84 Million USD | -18125.362% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -4118.228% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -2190.282% |
| Gritstone bio, Inc. | 177.76 Million USD | -89.323% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -252.859% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -1784.178% |
| Insmed Incorporated | 1.32 Billion USD | 74.692% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -3395.481% |
| MediWound Ltd. | 66.45 Million USD | -406.413% |
| OmniAb, Inc. | 401.98 Million USD | 16.276% |
| Alector, Inc. | 621.82 Million USD | 45.876% |
| Seres Therapeutics, Inc. | 358.6 Million USD | 6.147% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -6158.033% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -493.659% |
| Zai Lab Limited | 1.03 Billion USD | 67.523% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 29.657% |
| Aura Biosciences, Inc. | 255.07 Million USD | -31.944% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 55.127% |
| Immunic, Inc. | 54.29 Million USD | -519.822% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -26.419% |
| Veracyte, Inc. | 1.13 Billion USD | 70.421% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -2746.682% |
| FibroGen, Inc. | 423.52 Million USD | 20.535% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -9480.33% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -7005.448% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -6098.699% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 97.046% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -3722.34% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 34.959% |
| TG Therapeutics, Inc. | 329.58 Million USD | -2.115% |
| Galecto, Inc. | 38.22 Million USD | -780.417% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1073.654% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 92.276% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -42.97% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1254.79% |
| XBiotech Inc. | 227.24 Million USD | -48.104% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -252.859% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -136.015% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -17.712% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -163.205% |
| Theravance Biopharma, Inc. | 381.99 Million USD | 11.896% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 77.428% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | 7.753% |
| Vaxxinity, Inc. | 44.35 Million USD | -658.815% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 34.897% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -1708.539% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -10.328% |
| NexImmune, Inc. | 8.59 Million USD | -3816.209% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -3040.934% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -1865.022% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.983% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1419.367% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -85698.376% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -94.172% |
| Ainos, Inc. | 31.84 Million USD | -956.966% |
| Pluri Inc. | 39.52 Million USD | -751.461% |
| Prothena Corporation plc | 696.38 Million USD | 51.671% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -19.086% |
| Celularity Inc. | 143.88 Million USD | -133.9% |
| Rallybio Corporation | 115.62 Million USD | -191.089% |
| Cue Biopharma, Inc. | 61.53 Million USD | -446.98% |
| MeiraGTx Holdings plc | 458.16 Million USD | 26.543% |
| Omeros Corporation | 378.26 Million USD | 11.027% |
| Humacyte, Inc. | 128.22 Million USD | -162.478% |
| Immunocore Holdings plc | 597 Million USD | 43.625% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -976.672% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -391.109% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 67.924% |
| CalciMedica, Inc. | 12.18 Million USD | -2662.06% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -32.686% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -96.923% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -8.206% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 40.464% |
| Pulmatrix, Inc. | 33.95 Million USD | -891.098% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1139.803% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -138.934% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 74.13% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -158.514% |
| Cytokinetics, Incorporated | 824.31 Million USD | 59.171% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -1493.32% |
| Nutriband Inc. | 7.51 Million USD | -4377.186% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -326.27% |
| Vor Biopharma Inc. | 209.82 Million USD | -60.397% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 95.34% |
| Evogene Ltd. | 51.1 Million USD | -558.611% |
| ProKidney Corp. | 420.55 Million USD | 19.973% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -513.785% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -3435.159% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 38.402% |
| CorMedix Inc. | 82.05 Million USD | -310.135% |
| BioLineRx Ltd. | 63.92 Million USD | -426.487% |
| Tango Therapeutics, Inc. | 402.56 Million USD | 16.397% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1093.465% |
| Atai Life Sciences N.V. | 293.47 Million USD | -14.679% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -106.313% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -164.136% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 40.117% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -247.974% |
| MediciNova, Inc. | 66.26 Million USD | -407.857% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -282.677% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -7442.122% |
| GeoVax Labs, Inc. | 9.28 Million USD | -3525.434% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 42.785% |
| Biomea Fusion, Inc. | 199.92 Million USD | -68.34% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 82.316% |
| Mereo BioPharma Group plc | 66.49 Million USD | -406.108% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 30.621% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 45.086% |
| Absci Corporation | 234.48 Million USD | -43.533% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -4500.916% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | 0.981% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -103.873% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 36.055% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -21.198% |
| Allakos Inc. | 243.61 Million USD | -38.154% |
| Imunon, Inc. | 21.91 Million USD | -1435.523% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -30.603% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 45.849% |
| BioAtla, Inc. | 119.65 Million USD | -181.266% |
| NLS Pharmaceutics AG | 1.84 Million USD | -18125.362% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -10352.081% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 47.645% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -250.818% |
| XOMA Corporation | 234.3 Million USD | -43.643% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -52.126% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -167.44% |
| aTyr Pharma, Inc. | 122.06 Million USD | -175.715% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -118.681% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 42.0% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 31.374% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -204.662% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2120.39% |
| Akari Therapeutics, Plc | 4.35 Million USD | -7628.06% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1875.409% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 80.583% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -10813.052% |
| UroGen Pharma Ltd. | 178.31 Million USD | -88.747% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 28.504% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -60462.878% |
| Orgenesis Inc. | 14.55 Million USD | -2212.789% |
| Entera Bio Ltd. | 11.76 Million USD | -2760.663% |
| GH Research PLC | 226.3 Million USD | -48.722% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -515.345% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -213.263% |
| Xencor, Inc. | 952.69 Million USD | 64.673% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -4223.83% |
| Replimune Group, Inc. | 487.72 Million USD | 30.994% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -4069.908% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 48.097% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -10813.052% |
| Portage Biotech Inc. | 7.77 Million USD | -4226.482% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -7442.122% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -21.525% |
| OncoCyte Corporation | 74.89 Million USD | -349.39% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -16452.678% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -5716.101% |
| Purple Biotech Ltd. | 44.3 Million USD | -659.688% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -886.219% |
| scPharmaceuticals Inc. | 94.47 Million USD | -256.224% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -1765.103% |
| HilleVax, Inc. | 344.43 Million USD | 2.287% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -10496.883% |
| Tharimmune, Inc. | 10.94 Million USD | -2974.593% |
| Genprex, Inc. | 10.67 Million USD | -3054.061% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 32.172% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -249.662% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -13772.918% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -7979.745% |
| OKYO Pharma Limited | 1.54 Million USD | -21736.428% |
| Savara Inc. | 177.56 Million USD | -89.541% |
| Curis, Inc. | 77.28 Million USD | -335.492% |
| Daré Bioscience, Inc. | 21.28 Million USD | -1481.4% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -426.291% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -4062.219% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -1637.427% |
| BeiGene, Ltd. | 5.8 Billion USD | 94.203% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -2665.692% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 83.886% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | 5.977% |
| Erasca, Inc. | 395.29 Million USD | 14.86% |
| bluebird bio, Inc. | 619.16 Million USD | 45.643% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -7684.6% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 95.081% |
| DBV Technologies S.A. | 182.98 Million USD | -83.925% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -7684.6% |
| Moderna, Inc. | 18.42 Billion USD | 98.173% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -1747.489% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -2804.859% |
| Molecular Templates, Inc. | 35.38 Million USD | -851.183% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -143.414% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 57.339% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -10.799% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -223.781% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 27.72% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -7.376% |
| MacroGenics, Inc. | 306.82 Million USD | -9.692% |
| RenovoRx, Inc. | 1.46 Million USD | -22857.503% |
| Adicet Bio, Inc. | 207.29 Million USD | -62.357% |
| Prime Medicine, Inc. | 193.85 Million USD | -73.616% |
| Aditxt, Inc. | 44.57 Million USD | -654.979% |
| Adagene Inc. | 115.72 Million USD | -190.815% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -7455.966% |
| Quantum-Si incorporated | 298.25 Million USD | -12.844% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 77.374% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -4265.698% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | 4.192% |
| SciSparc Ltd. | 11.18 Million USD | -2909.81% |
| Vericel Corporation | 353.65 Million USD | 4.835% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -2655.816% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -491.482% |
| Generation Bio Co. | 374.75 Million USD | 10.194% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -32.156% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -112.249% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | 1.408% |
| Invivyd, Inc. | 229.18 Million USD | -46.852% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 60.123% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -2665.623% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -84.526% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -1547.851% |
| 2seventy bio, Inc. | 565.42 Million USD | 40.477% |
| ADMA Biologics, Inc. | 329.18 Million USD | -2.24% |
| Clene Inc. | 52.34 Million USD | -543.008% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -473.016% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -159.101% |
| GeoVax Labs, Inc. | 9.28 Million USD | -3525.434% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 48.515% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -224.827% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -158.124% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -245.003% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -374.044% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -38.756% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 82.83% |
| Evaxion Biotech A/S | 12.88 Million USD | -2511.273% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -33.523% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 55.286% |
| Trevena, Inc. | 40.6 Million USD | -728.856% |
| Surrozen, Inc. | 46.08 Million USD | -630.375% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -49.013% |
| Cingulate Inc. | 3.49 Million USD | -9539.501% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -1923.916% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -412.341% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -2780.34% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -25.339% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 55.063% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -167.338% |
| Clearmind Medicine Inc. | 4.32 Million USD | -7682.764% |
| Kronos Bio, Inc. | 213.27 Million USD | -57.801% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -110.632% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -3831.46% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 8.666% |
| Statera Biopharma, Inc. | 21.16 Million USD | -1489.806% |
| ImmunityBio, Inc. | 504.45 Million USD | 33.283% |
| Korro Bio, Inc. | 221.66 Million USD | -51.833% |
| Kineta, Inc. | 10.28 Million USD | -3173.582% |
| BioVie Inc. | 25.2 Million USD | -1235.102% |
| Codexis, Inc. | 136.56 Million USD | -146.452% |
| Celularity Inc. | 143.88 Million USD | -133.9% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 47.028% |
| Celcuity Inc. | 191.21 Million USD | -76.006% |
| Virax Biolabs Group Limited | 5.48 Million USD | -6037.106% |
| Cibus, Inc. | 544.41 Million USD | 38.18% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -167.334% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -1538.225% |
| IN8bio, Inc. | 33.7 Million USD | -898.419% |
| Kodiak Sciences Inc. | 479.37 Million USD | 29.792% |
| Annexon, Inc. | 297.67 Million USD | -13.062% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -94.53% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -144.824% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -1503.187% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 88.744% |
| Eyenovia, Inc. | 28.77 Million USD | -1069.438% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -45.994% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -4558.873% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -452.403% |
| Arcellx, Inc. | 825.13 Million USD | 59.212% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -312.26% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | 27.196% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -994.494% |
| Moolec Science SA | 24.05 Million USD | -1299.33% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -8.523% |
| Geron Corporation | 394.07 Million USD | 14.596% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -230.899% |
| Royalty Pharma plc | 16.38 Billion USD | 97.946% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 43.433% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -4711.521% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -2698.272% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -48.88% |
| Humacyte, Inc. | 128.22 Million USD | -162.478% |
| Structure Therapeutics Inc. | 482.01 Million USD | 30.177% |
| 89bio, Inc. | 596.26 Million USD | 43.556% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -33.474% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -18092.27% |
| Genelux Corporation | 27.89 Million USD | -1106.6% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -276.449% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -46.693% |
| Notable Labs, Ltd. | 19.54 Million USD | -1622.312% |
| Liquidia Corporation | 120.43 Million USD | -179.46% |
| Mustang Bio, Inc. | 17.74 Million USD | -1796.951% |
| Immunovant, Inc. | 666.71 Million USD | 49.52% |
| Quantum-Si incorporated | 298.25 Million USD | -12.844% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -133.071% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -521.412% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -91.72% |
| Acasti Pharma Inc. | 73.3 Million USD | -359.15% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -7293.151% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1188.658% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 65.116% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -6384.823% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1377.358% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -552.204% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -86.261% |
| PepGen Inc. | 143.05 Million USD | -135.269% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -780.647% |
| United Therapeutics Corporation | 7.16 Billion USD | 95.304% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -1654.272% |
| Solid Biosciences Inc. | 164.93 Million USD | -104.049% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -5631.302% |
| Immuneering Corporation | 102.58 Million USD | -228.078% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -7711.248% |
| Silo Pharma, Inc. | 7.74 Million USD | -4244.834% |
| Belite Bio, Inc | 94.64 Million USD | -255.611% |
| XOMA Corporation | 234.3 Million USD | -43.643% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -44.329% |
| Bionomics Limited | 27.64 Million USD | -1117.244% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | 16.155% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -213.403% |
| uniQure N.V. | 831.68 Million USD | 59.533% |
| Cassava Sciences, Inc. | 151.66 Million USD | -121.911% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -7455.966% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -22.883% |
| Forte Biosciences, Inc. | 38.98 Million USD | -763.409% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -8162.892% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -813.787% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -4558.873% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -9480.33% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -2747.111% |
| Altimmune, Inc. | 210.64 Million USD | -59.778% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 56.734% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -213.403% |
| Compugen Ltd. | 121.33 Million USD | -177.381% |
| Peak Bio, Inc. | 2.59 Million USD | -12862.373% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -95.301% |
| Benitec Biopharma Inc. | 52.21 Million USD | -544.622% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | 1.551% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -867.869% |
| Zura Bio Limited | 100.84 Million USD | -233.744% |
| PolyPid Ltd. | 15.37 Million USD | -2089.416% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -182.143% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -867.869% |
| Instil Bio, Inc. | 325.63 Million USD | -3.356% |
| argenx SE | 4.54 Billion USD | 92.591% |
| Immunome, Inc. | 148.54 Million USD | -126.577% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -114.538% |
| Verona Pharma plc | 308.12 Million USD | -9.228% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -287.03% |
| Shattuck Labs, Inc. | 159.56 Million USD | -110.923% |
| CervoMed Inc. | 9.97 Million USD | -3274.844% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -78.587% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -2855.365% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -87.596% |
| Moolec Science SA | 24.05 Million USD | -1299.33% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -5401.563% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -94.604% |
| AnaptysBio, Inc. | 452.38 Million USD | 25.605% |
| Design Therapeutics, Inc. | 289.64 Million USD | -16.197% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -362.145% |
| NeurAxis, Inc. | 509.49 Thousand USD | -65956.589% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -6111.831% |
| Lumos Pharma, Inc. | 40.63 Million USD | -728.183% |
| Achilles Therapeutics plc | 161.45 Million USD | -108.451% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -287.03% |
| 180 Life Sciences Corp. | 5.25 Million USD | -6299.06% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -377.875% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -3831.46% |
| Nutriband Inc. | 7.51 Million USD | -4377.186% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -32.146% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -68.869% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -341.606% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -481.112% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 36.081% |
| Palisade Bio, Inc. | 14.05 Million USD | -2295.083% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -60.04% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 76.944% |
| Neurogene Inc. | 222.57 Million USD | -51.212% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 47.951% |
| AEON Biopharma, Inc. | 6.84 Million USD | -4816.83% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | 25.711% |
| Sesen Bio, Inc. | 189.17 Million USD | -77.909% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -23.795% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -2354.494% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 56.871% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -26.054% |
| Athira Pharma, Inc. | 160.24 Million USD | -110.027% |
| Vaccinex, Inc. | 3.63 Million USD | -9168.989% |
| HCW Biologics Inc. | 28.51 Million USD | -1080.336% |
| XOMA Corporation | 234.3 Million USD | -43.643% |
| Nektar Therapeutics | 398.03 Million USD | 15.445% |
| Arvinas, Inc. | 1.3 Billion USD | 74.202% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -1875.409% |
| Merus N.V. | 458.49 Million USD | 26.595% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -64.683% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -86.764% |
| Rezolute, Inc. | 132.73 Million USD | -153.552% |
| Clene Inc. | 52.34 Million USD | -543.008% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -2155.158% |
| BeyondSpring Inc. | 24.8 Million USD | -1256.647% |
| Synlogic, Inc. | 75.55 Million USD | -345.476% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -2737.27% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -3494.158% |
| Peak Bio, Inc. | 2.59 Million USD | -12862.373% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -92.502% |
| Krystal Biotech, Inc. | 818.35 Million USD | 58.874% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -39.977% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 53.629% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -9308.46% |
| MannKind Corporation | 475.19 Million USD | 29.175% |
| Ikena Oncology, Inc. | 192.09 Million USD | -75.206% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -2416.502% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -188.793% |
| Gossamer Bio, Inc. | 311.91 Million USD | -7.9% |
| CohBar, Inc. | 16.36 Million USD | -1956.482% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -857.134% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -4500.916% |
| Legend Biotech Corporation | 1.84 Billion USD | 81.794% |
| Mural Oncology plc | 301.74 Million USD | -11.537% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -978.19% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -5824.877% |
| Disc Medicine, Inc. | 367.99 Million USD | 8.543% |
| Champions Oncology, Inc. | 26.13 Million USD | -1187.911% |
| REGENXBIO Inc. | 573.97 Million USD | 41.363% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -12327.86% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -117.997% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -2687.088% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | 1.023% |
| Vaxart, Inc. | 91.83 Million USD | -266.5% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -461.828% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -126.902% |
| Cellectis S.A. | 334.27 Million USD | -0.684% |
| Longeveron Inc. | 12.17 Million USD | -2663.648% |
| Repare Therapeutics Inc. | 253.9 Million USD | -32.554% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 89.691% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -67.569% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 83.886% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -20611.2% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -21.19% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -106.353% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -142.574% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1218.694% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.519% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 70.834% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -2655.816% |
| Veru Inc. | 50.59 Million USD | -565.186% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -638.825% |
| Cingulate Inc. | 3.49 Million USD | -9539.501% |
| Passage Bio, Inc. | 150.54 Million USD | -123.559% |
| Context Therapeutics Inc. | 16.06 Million USD | -1995.266% |
| Exicure, Inc. | 11.58 Million USD | -2806.364% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | 10.502% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -108.211% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -1826.265% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -1.146% |
| Nuvalent, Inc. | 732.38 Million USD | 54.046% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2152.109% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -275.815% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -2271.623% |
| OmniAb, Inc. | 401.98 Million USD | 16.276% |
| Anew Medical, Inc. | 19.45 Million USD | -1629.841% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1159.261% |
| Lipocine Inc. | 23 Million USD | -1363.223% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -140.73% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -10.143% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -300.944% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -176.91% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -4141.424% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 61.854% |
| Ocugen, Inc. | 64.54 Million USD | -421.414% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -170.238% |
| Q32 Bio Inc. | 306.11 Million USD | -9.943% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -7898.028% |
| Alumis Inc. Common Stock | 89.61 Million USD | -275.571% |
| Equillium, Inc. | 50.53 Million USD | -566.054% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -347.579% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -715.431% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -19687.542% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1187.468% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -422.272% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -8929.965% |
| Dominari Holdings Inc. | 57.55 Million USD | -484.727% |
| Edesa Biotech, Inc. | 8.89 Million USD | -3685.607% |
| vTv Therapeutics Inc. | 11.01 Million USD | -2954.611% |
| Bio-Techne Corporation | 2.81 Billion USD | 88.036% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 64.086% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 58.524% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -21.21% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -707.052% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 49.586% |
| Nkarta, Inc. | 378.88 Million USD | 11.172% |
| BioCardia, Inc. | 2.98 Million USD | -11167.392% |
| Iterum Therapeutics plc | 26.25 Million USD | -1181.682% |